Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?
作者信息
Srinivas N R
机构信息
Suramus Bio, J.P. Nagar I Phase Bangalore, Karnataka, India.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):563. doi: 10.1002/psp4.12033. Epub 2015 Oct 9.
Abstract
摘要
相似文献
1
Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide: Should Consideration Be Given to Cannalicular Efflux Transporters?用于预测来氟米特和特立氟胺的基于生理的药代动力学模型：是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):563. doi: 10.1002/psp4.12033. Epub 2015 Oct 9.
2
Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?基于生理学的药代动力学模型对来氟米特和特立氟胺预测的反应——是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):564. doi: 10.1002/psp4.12036. Epub 2015 Oct 9.
3
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.类风湿关节炎患者中来氟米特处置的半生理药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.
4
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.来氟米特局部给药治疗类风湿性关节炎：在关节炎大鼠模型中评价托法替布的局部组织沉积及其抗炎作用。
Drug Dev Ind Pharm. 2016;42(2):254-62. doi: 10.3109/03639045.2015.1044906. Epub 2015 May 26.
5
Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.肝微粒体细胞色素P450酶和钠/胆汁酸共转运体的抑制会加重来氟米特诱导的肝毒性。
Acta Pharmacol Sin. 2016 Mar;37(3):415-24. doi: 10.1038/aps.2015.157. Epub 2016 Jan 25.
6
Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.来氟米特和特立氟胺：改变嘧啶代谢以治疗自身免疫性疾病。
Expert Rev Clin Pharmacol. 2015 May;8(3):315-20. doi: 10.1586/17512433.2015.1019343. Epub 2015 Feb 24.
7
On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.来氟米特与特立氟胺在受体腔内的相互作用——核磁共振研究与能量计算
J Mol Model. 2015 May;21(5):105. doi: 10.1007/s00894-015-2643-z. Epub 2015 Apr 8.
8
Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.特立氟胺（奥巴捷）。多发性硬化症：只是来氟米特的一种代谢产物。
Prescrire Int. 2015 Mar;24(158):61-4.
9
Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.特立氟胺（奥巴捷®）用于治疗多发性硬化症。
Exp Neurol. 2014 Dec;262 Pt A:57-65. doi: 10.1016/j.expneurol.2014.06.005. Epub 2014 Jun 10.
10
Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.特立氟胺，一种二氢乳清酸脱氢酶抑制剂，用于多发性硬化症的潜在口服治疗。
Curr Opin Investig Drugs. 2010 Nov;11(11):1313-23.
引用本文的文献
1
Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?基于生理学的药代动力学模型对来氟米特和特立氟胺预测的反应——是否应考虑小管外排转运体？
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):564. doi: 10.1002/psp4.12036. Epub 2015 Oct 9.
本文引用的文献
1
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.类风湿关节炎患者中来氟米特处置的半生理药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.
2
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance.来氟米特及其代谢产物A771726是乳腺癌耐药蛋白（BCRP）的高亲和力底物：对耐药性的影响。
Ann Rheum Dis. 2009 Jul;68(7):1201-7. doi: 10.1136/ard.2007.086264. Epub 2008 Apr 8.
3
Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats.肝细胞胆小管共轭转运泵（Mrp2）对亚砷酸钠诱导的大鼠肝功能障碍的保护作用。
Exp Toxicol Pathol. 2007 Aug;58(6):447-53. doi: 10.1016/j.etp.2007.02.001. Epub 2007 Apr 30.
4
Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury.吲哚美辛诱导的大鼠肠道损伤中肝脏BSP转运体的下调
Biol Pharm Bull. 2007 Mar;30(3):556-61. doi: 10.1248/bpb.30.556.
5
Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene.对乙酰氨基酚在Mrp3基因敲除小鼠体内的处置改变。
Hepatology. 2005 Nov;42(5):1091-8. doi: 10.1002/hep.20898.
Zotero 插件